Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10188933" target="_blank" >RIV/00216208:11110/13:10188933 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/13:10188933

Výsledek na webu

<a href="http://dx.doi.org/10.1111/add.12219" target="_blank" >http://dx.doi.org/10.1111/add.12219</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/add.12219" target="_blank" >10.1111/add.12219</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy

Popis výsledku v původním jazyce

Background and aims Cross-study comparisons of effect sizes suggest that varenicline is more effective than nicotine replacement therapy (NRT) in aiding smoking cessation, but evidence from direct comparisons is limited. This study compared biochemicallyverified 52-week sustained abstinence rates in smokers attending the same clinical service according to whether they used varenicline or NRT in their quit attempt. Methods This was a prospective cohort study of 855 smokers attending a large smoking cessation clinic who used their choice of NRT product or varenicline in their quit attempt. All received the same behavioural support programme and chose their medication option (n=519 varenicline; n=336 NRT). The primary outcome measure was self-report of 52 weeks' abstinence following the target quit date confirmed by expired air carbon monoxide concentration. Baseline measures included socio-demographic variables, mental health diagnoses, measures of smoking, cigarette dependence and past

Název v anglickém jazyce

Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy

Popis výsledku anglicky

Background and aims Cross-study comparisons of effect sizes suggest that varenicline is more effective than nicotine replacement therapy (NRT) in aiding smoking cessation, but evidence from direct comparisons is limited. This study compared biochemicallyverified 52-week sustained abstinence rates in smokers attending the same clinical service according to whether they used varenicline or NRT in their quit attempt. Methods This was a prospective cohort study of 855 smokers attending a large smoking cessation clinic who used their choice of NRT product or varenicline in their quit attempt. All received the same behavioural support programme and chose their medication option (n=519 varenicline; n=336 NRT). The primary outcome measure was self-report of 52 weeks' abstinence following the target quit date confirmed by expired air carbon monoxide concentration. Baseline measures included socio-demographic variables, mental health diagnoses, measures of smoking, cigarette dependence and past

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ME09014" target="_blank" >ME09014: Léčba závislosti na tabáku v České republice podle zkušeností The Mayo Nicotine Dependence Center (NDC): systematická implementace a vyhodnocování, porovnání výsledků s NDC</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Addiction

ISSN

0965-2140

e-ISSN

—

Svazek periodika

108

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

1497-1502

Kód UT WoS článku

000321616800022

EID výsledku v databázi Scopus

—